ANDA 77372, held by Sun Pharm Inds. Octreotide Acetate.
As of Nov 16, 2026, ANDA 77372 (Octreotide Acetate), held by Sun Pharm Inds, was first approved by FDA on Aug 14, 2007, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2007 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.05MG BASE/ML · injectable;injection | Octreotide Acetate | Discontinued |
| Octreotide AcetateEQ 0.1MG BASE/ML · injectable;injection | Octreotide Acetate | Discontinued |
| Octreotide AcetateEQ 0.5MG BASE/ML · injectable;injection | Octreotide Acetate | Discontinued |
| Jun 28, 2017 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 31, 2013 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 30, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 14, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters